Results from the EXCAAPE clinical trial were presented at ESMO 2020. The poster presentation summarized the main results of this MEDSIR-sponsored clinical trial (NCT03002220) which evaluated Radium-223 (223Ra) for the treatment of asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients with bone metastases and no visceral involvement, and who had previously progressed to abiraterone acetate or enzalutamide.
Investigators from 9 hospitals in Spain enrolled a total of 52 patients who were treated with 223Ra, administered at four-week intervals for six cycles. This single-arm, open-label, non-controlled phase IIa study aimed to assess the activity and safety of 223Ra and the association between Androgen Receptor splice variant 7 (AR-V7) status and treatment efficacy.
Results from the EXCAAPE trial indicate that 223Ra is active and safe for 2nd line treatment in asymptomatic mCRPC patients with bone metastasis who have progressed to 1st line new hormonal regimens.
The EXCAAPE study was led by Dr. Joan Carles Galcerán from the Medical Oncology Department at the Vall d’Hebron Institute of Oncology in Barcelona, as the scientific coordinator and main author of the results presented.
“Prostate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death among men worldwide. Androgen deprivation therapy (ADT) is the current standard of care for metastatic prostate cancer. However, initial treatment responses to ADT are transitory and patients often progress to mCRPC. That is why it is important to continue working towards finding new treatments and biomarkers for the most advanced cases” said Dr. Carles Galcerán.
Contact us to hear more about our work and clinical trials to find better treatments for prostate cancer patients.